{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.9","value":"5.628"},{"groupId":"OG001","spread":"20.6","value":"5.176"},{"groupId":"OG002","spread":"23.8","value":"5.088"},{"groupId":"OG003","spread":"20.2","value":"5.954"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"}],"units":"Participants"}],"description":"Blood samples for pharmacokinetic analysis of GSK525762 were collected at the indicated time points.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered GSK525762 80 mg amorphous free-base tablet along with 6 mg stable isotope in the fasted state.","id":"OG000","title":"GSK525762 80 mg Amorphous+6 mg Stable Isotope"},{"description":"Participants were administered GSK525762 80 mg besylate tablet along with 6 mg stable isotope in solution in fasted state.","id":"OG001","title":"GSK525762 80 mg Besylate+6 mg Stable Isotope"},{"description":"Participants were administered GSK525762 30 mg besylate tablet along with 6 mg stable isotope in solution in fasted state.","id":"OG002","title":"GSK525762 30 mg Besylate+6 mg Stable Isotope"},{"description":"Participants were administered GSK525762 80 mg besylate tablet along with Food and Drug Administration (FDA) recommended high fat breakfast.","id":"OG003","title":"GSK525762 80 mg Besylate Fed"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Besylate Sub-Study PK Parameter Population. Only those participants with data available at the specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Week1 Day1, Day3 and Week2 Day1 (pre-dose,0.25,0.5,1,1.5,2,3,4,6,8,24,48 hours post-dose)","title":"Apparent Terminal Phase Elimination Rate Constant (Lambda z) for GSK525762-Besylate Sub-study","type":"PRIMARY","unitOfMeasure":"Per hour"}